Email updates

Keep up to date with the latest news and content from Infectious Agents and Cancer and BioMed Central.

This article is part of the supplement: Proceedings of the 11th International Conference on Malignancies in AIDS and Other Acquired Immunodeficiencies (ICMAOI): Basic, Epidemiologic, and Clinical Research

Open Access Poster presentation

Immunophenotypic analysis of AIDS-related diffuse large B-cell lymphoma and clinical implications in patients from AIDS malignancies consortium clinical trials 010 and 034

A Chadburn1*, A Chiu1, Y Lee2, X Chen1, E Hyjek1, A Banhmam3, A Noy4, A Kaplan5, J Sparano6, K Bhatia7, E Cesarman1 and the Aids Malignancy Consortium

  • * Corresponding author: A Chadburn

Author Affiliations

1 Weill Cornell Medical College, New York, New York, USA

2 University of Alabama at Birmingham, Birmingham, Alabama, USA

3 Nuffield Department of Clinical Laboratory Sciences, University of Oxford, Headington, Oxford, UK

4 Memorial Sloan Kettering Cancer Center, New York, New York, USA

5 University of California-San Francisco, San Francisco, California, USA

6 Albert Einstein Comprehensive Cancer Center, New York, New York, USA

7 National Cancer Institute, National Institutes of Health Washington, D.C., USA

For all author emails, please log on.

Infectious Agents and Cancer 2009, 4(Suppl 2):P14  doi:10.1186/1750-9378-4-S2-P14

The electronic version of this article is the complete one and can be found online at: http://www.infectagentscancer.com/content/4/S2/P14


Published:17 June 2009

© 2009 Chadburn et al; licensee BioMed Central Ltd.

Poster presentation

Diffuse large B cell lymphoma represents a clinically heterogeneous disease, and several immunohistochemical strategies have been shown to help prognosticate clinical outcome. These include subdivision into germinal center (GC) and non-germinal center (non-GC) subtypes, proliferation index (measured by expression of Ki67), and expression of BCL-2, FOXP1 or Blimp-1/PRDM1. We sought to determine whether immunohistochemical analyses of biopsies from DLBCL patients with HIV infection are similarly relevant for prognostication.

We examined 82 DLBCLs from uniformly treated AIDS patients in AMC 010 (CHOP or CHOP-rituximab) and AMC 034 (EPOCH-rituximab) clinical trials, and compared the immunophenotype with survival data, Epstein Barr virus (EBV) positivity and CD4 counts. There was no significant difference in survival or CD4 counts between the patients with GC and non-GC subtypes of DLBCL, regardless of inclusion of rituximab in the treatment regimen. EBV assessment showed that this virus can be found in both subtypes of DLBCL, although less frequently in the GC subtype, and does not affect survival.

We also evaluated expression FOXP1, which is an independent adverse prognostic marker when expressed in immunocompetent patients with DLBCL, as well as expression of Blimp-1/PRDM1 and BCL-2. Expression of FOXP1, Blimp-1/PRDM1 or BCL-2 did not correlate with the outcome in patients with AIDS-related DLBCL. The only predictive immunohistochemical marker was found to be Ki67, where a higher proliferation index was associated with better survival suggesting a better response to therapy in patients whose tumors had higher proliferation rates. These data indicate that with current treatment strategies for lymphoma and control of HIV infection, commonly used immunohistochemical markers may not be clinically relevant in HIV-infected DLBCL patients.